Ziv-Aflibercept 25mg/ml Suppliers & Bulk Manufacturers

Available Forms: Intravenous (IV)

Available Strengths: 25mg/ml

Reference Brands: Zaltrap® (US & EU)

Category: Oncology Cancer Care

Ziv-aflibercept 25 mg/mL concentrate for IV infusion, a VEGF trap fusion protein given with FOLFIRI in metastatic colorectal cancer. For hospital oncology pharmacies and importers with a 2-8°C cold chain.

Product Description:

Ziv-aflibercept is a recombinant fusion protein joining the VEGF-binding parts of human VEGF receptors 1 and 2 to the Fc portion of human IgG1. It acts as a soluble decoy, trapping VEGF-A, VEGF-B and placental growth factor so they cannot drive new tumour blood vessels. It is a 25 mg/mL concentrate in single-use vials of 100 mg/4 mL and 200 mg/8 mL, diluted for intravenous infusion. The ziv- prefix was added in the United States to keep it apart from the eye product: this concentrate is hyperosmotic and must never be injected into the eye.

It is given with FOLFIRI (irinotecan, fluorouracil and folinic acid) to adults with metastatic colorectal cancer that has progressed on or after an oxaliplatin-based regimen. The dose is weight-based and infused over one hour every two weeks through a 0.2 micron filter. VEGF blockade shapes the safety profile: bleeding, gastrointestinal perforation, poor wound healing, high blood pressure, proteinuria and arterial thrombosis. Treatment stops at least four weeks before planned surgery. Blood pressure and urine protein are checked before every dose.

Sourcing notes. As a biological medicine it needs an unbroken cold chain at 2-8°C, protected from light and never frozen, so ask for temperature logger data with each shipment. Registration covers the United States, the European Union and a number of other markets; elsewhere supply runs through named-patient routes. Request the batch CoA, batch release certificate, GMP certificate and CoPP, with a traceable supply chain. State the vial size, since weight-based dosing decides which vial wastes less.